argenx | argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG We are pleased to share an important update from argenx regarding the treatment landscape for generalized myasthenia gravis (gMG). The U.S. Food and Drug Administration (FDA) has approved a label expansion for VYVGART (efgartigimod… Read more »
Posts By: Giselle Murillo
Monica Seles Speaks Out About Living with Myasthenia Gravis and partners with argenx in the Go for Greater initiative
Nine-time Grand Slam champion Monica Seles has revealed her diagnosis with myasthenia gravis (MG), which she has been living with since 2022. She first noticed symptoms such as double vision and weakness in her arms and legs, which made everyday tasks difficult, and is now using her platform to educate and support others. Partnering… Read more »
Read study results on patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations
Scientific Reports shares results from a study that looks at disease burden. Public domain digital conversations about MG were analyzed to describe mindsets and sentiments about the disease, its burden, and its treatments among men and women with MG and, more specifically, those treated with steroids and those receiving IVIg.
